PE20030740A1 - Uso de una dosis especifica de fondaparinux sodio para el tratamiento de los sindromes coronarios agudos - Google Patents

Uso de una dosis especifica de fondaparinux sodio para el tratamiento de los sindromes coronarios agudos

Info

Publication number
PE20030740A1
PE20030740A1 PE2002001086A PE2002001086A PE20030740A1 PE 20030740 A1 PE20030740 A1 PE 20030740A1 PE 2002001086 A PE2002001086 A PE 2002001086A PE 2002001086 A PE2002001086 A PE 2002001086A PE 20030740 A1 PE20030740 A1 PE 20030740A1
Authority
PE
Peru
Prior art keywords
treatment
sulfo
acute coronary
coronary syndromes
specific dose
Prior art date
Application number
PE2002001086A
Other languages
English (en)
Inventor
Anthonie Wilhelmus Arnold Lensing
Original Assignee
Sanofi Synthelabo
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=8181220&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PE20030740(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Sanofi Synthelabo filed Critical Sanofi Synthelabo
Publication of PE20030740A1 publication Critical patent/PE20030740A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7024—Esters of saccharides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/702—Oligosaccharides, i.e. having three to five saccharide radicals attached to each other by glycosidic linkages
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Polysaccharides And Polysaccharide Derivatives (AREA)

Abstract

SE REFIERE AL USO DE UNA DOSIS DE 2,5mg DE PENTASACARIDO METIL O-(2-DESOXI-2-SULFOAMINO-6-O-SULFO-O-D-GLUCOPIRANOSILO)-(1-4)-O-(ACIDO ß-D-GLUCOPIRANOSIL URONICO)-(1-4)-O-(2-DESOXI-2-SULFOAMINO-3,6-DI-O-SULFO-O-D-GLUCOPIRANOSILO)- (1-4)-O-(ACIDO-2-O-SULFO-O-L-IDOPIRANOSIL-URONICO)-(1-4)-2-DESOXI-2-SULFOAMINO-6-O-SULFO-O-D-GLUCO-PIRANOSIDO (FONDAPARINUX) CARACTERIZADO PORQUE EL PENTASACARIDO ESTA EN FORMA DE SU SAL DECASODICA Y ES UTIL PARA EL TRATAMIENTO DE SINDROMES CORONARIOS AGUDOS (ACS) SIN ELEVACION DEL SEGMENTO ST ANGINA INESTABLE/INFARTO AGUDO AL MIOCARDIO
PE2002001086A 2001-11-13 2002-11-07 Uso de una dosis especifica de fondaparinux sodio para el tratamiento de los sindromes coronarios agudos PE20030740A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP01204323 2001-11-13

Publications (1)

Publication Number Publication Date
PE20030740A1 true PE20030740A1 (es) 2003-08-28

Family

ID=8181220

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2002001086A PE20030740A1 (es) 2001-11-13 2002-11-07 Uso de una dosis especifica de fondaparinux sodio para el tratamiento de los sindromes coronarios agudos

Country Status (37)

Country Link
US (1) US20040248848A1 (es)
EP (1) EP1446131B1 (es)
JP (1) JP4523276B2 (es)
KR (1) KR20050044318A (es)
CN (1) CN1602197A (es)
AP (1) AP1820A (es)
AR (1) AR037291A1 (es)
AT (1) ATE361753T1 (es)
AU (1) AU2002351915B2 (es)
BR (1) BR0212915A (es)
CA (1) CA2465776A1 (es)
CO (1) CO5580790A2 (es)
CY (1) CY1106765T1 (es)
DE (1) DE60220084T2 (es)
DK (1) DK1446131T3 (es)
EA (1) EA007325B1 (es)
EC (1) ECSP045041A (es)
ES (1) ES2287343T3 (es)
GE (1) GEP20074097B (es)
HK (1) HK1070561A1 (es)
HR (1) HRP20040303B1 (es)
HU (1) HU228959B1 (es)
IL (2) IL161114A0 (es)
IS (1) IS2484B (es)
MA (1) MA27071A1 (es)
ME (2) MEP1108A (es)
MX (1) MXPA04003045A (es)
NO (1) NO20041320L (es)
NZ (1) NZ552129A (es)
PE (1) PE20030740A1 (es)
PL (1) PL206008B1 (es)
PT (1) PT1446131E (es)
RS (1) RS50906B (es)
SI (1) SI1446131T1 (es)
UA (1) UA80399C2 (es)
WO (1) WO2003041722A1 (es)
ZA (1) ZA200402464B (es)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20090075910A1 (en) * 2007-09-13 2009-03-19 Protia, Llc Deuterium-enriched fondaparinux
EP3973958A3 (en) * 2015-03-20 2022-06-22 Aarhus Universitet Inhibitors of pcsk9 for treatment of lipoprotein metabolism disorders
US10688249B2 (en) * 2015-06-11 2020-06-23 Virchow Biotech Pvt. Ltd. Multiple dose pharmaceutical compositions containing heparin and/or heparin-like compounds and devices and methods for delivering the same
CN107595769A (zh) * 2017-10-23 2018-01-19 上海博悦生物科技有限公司 一种磺达肝癸钠注射液组合物的制备方法

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2662442A1 (fr) * 1990-05-23 1991-11-29 Midy Spa Trifluoromethylphenyltetrahydropyridines n-substituees procede pour leur preparation, intermediaires du procede et compositions pharmaceutiques les contenant.
CA2199642C (en) * 1997-03-10 2001-05-08 Roger Cariou Compositions containing an association of aspirin and an anti-xa oligosaccharide and use of an anti-xa oligosaccharide optionally in combination with aspirin
FR2764511B1 (fr) * 1997-06-13 2000-09-08 Sanofi Sa Compositions pour le traitement et la prevention de la thrombose arterielle et utilisation d'un inhibiteur du facteur xa seul et/ou en combinaison avec un antiagregant plaquettaire
EP1551852A4 (en) * 2002-04-25 2007-03-21 Momenta Pharmaceuticals Inc METHOD AND PRODUCTS FOR MUCOSAL DELIVERY

Also Published As

Publication number Publication date
AP1820A (en) 2008-01-11
ECSP045041A (es) 2004-04-28
JP2005509007A (ja) 2005-04-07
HU228959B1 (en) 2013-07-29
ZA200402464B (en) 2005-06-29
AR037291A1 (es) 2004-11-03
EA007325B1 (ru) 2006-08-25
MA27071A1 (fr) 2004-12-20
EP1446131B1 (en) 2007-05-09
EP1446131A1 (en) 2004-08-18
MXPA04003045A (es) 2005-06-20
DK1446131T3 (da) 2007-09-10
ME00229B (me) 2011-10-10
UA80399C2 (en) 2007-09-25
RS50906B (sr) 2010-08-31
WO2003041722A1 (en) 2003-05-22
PL369027A1 (en) 2005-04-18
ATE361753T1 (de) 2007-06-15
IS2484B (is) 2008-12-15
ES2287343T3 (es) 2007-12-16
CA2465776A1 (en) 2003-05-22
IS7199A (is) 2004-03-29
PT1446131E (pt) 2007-08-07
KR20050044318A (ko) 2005-05-12
HUP0401462A2 (en) 2006-02-28
CN1602197A (zh) 2005-03-30
PL206008B1 (pl) 2010-06-30
GEP20074097B (en) 2007-05-10
DE60220084D1 (de) 2007-06-21
BR0212915A (pt) 2004-10-13
AP2004003014A0 (en) 2004-06-30
SI1446131T1 (sl) 2007-10-31
CO5580790A2 (es) 2005-11-30
IL161114A0 (en) 2004-08-31
HK1070561A1 (en) 2005-06-24
CY1106765T1 (el) 2012-05-23
MEP1108A (en) 2011-02-10
IL161114A (en) 2010-11-30
NO20041320L (no) 2004-06-14
HRP20040303A2 (en) 2004-10-31
JP4523276B2 (ja) 2010-08-11
EA200400382A1 (ru) 2004-10-28
DE60220084T2 (de) 2008-01-10
US20040248848A1 (en) 2004-12-09
HRP20040303B1 (en) 2012-02-29
NZ552129A (en) 2008-04-30
RS26704A (en) 2007-02-05
AU2002351915B2 (en) 2007-11-29
HUP0401462A3 (en) 2006-04-28

Similar Documents

Publication Publication Date Title
ES2191766T3 (es) Composicion antiparasitaria para el tratamiento y la proteccion de los animales de compañia.
GT200000219A (es) Composiciones farmaceuticas que proporcionan concentraciones potenciadas de farmaco.
NO20014412D0 (no) Forbindelser nyttige som anti-inflammatoriske midler
NO20030550D0 (no) 17<beta>-karbotioat 17<alfa>-arylkarbonyloksyandrostanderivat som anti-inflammatoriske midler
CY1108101T1 (el) Ενωσεις πυριμιδινης και η χρηση τους στην παρασκευη ενος τριαζολο-πυριμιδιν καρβα νουκλεοζιτη
CY1111767T1 (el) Υδρογονωμενα παραγωγα βενζο[c]θειοφαινιου ως ανοσορρυθμιστες
SV2002000356A (es) Nuevos derivados de piperazina ref. pc10770aixn/bb
CY1105299T1 (el) Χρηση των επιλεκτικων αγωνιστων του υποδοχεα 4 (ep4) προσταγλανδινης (pge2) για τη θepαπεια της οξειας και χρονιας νεφρικης ανεπαρκειας
AR026304A1 (es) Proceso para la produccion de composiciones para el cuidado oral mediante el uso de polimeros dispersables aglomerados.
DK1379522T3 (da) Dihydro-benzo(b)(1,4)diazeping-2-on-derivater som MGLUR2-antagonister I
DK1078923T3 (da) Fremgangsmåde til fremstilling af benzothiophenderivater
CO5231147A1 (es) Composicion congelante
CY1107542T1 (el) Μiα ουσιαστικa κρυσταλλικh μορφh μελαγατρaνης
BR0007864A (pt) Composto, e, uso de um composto
ES2160680T3 (es) Utilizacion de un antagonista de sustancia p en una composicion farmaceutica.
PE20030740A1 (es) Uso de una dosis especifica de fondaparinux sodio para el tratamiento de los sindromes coronarios agudos
CY1107825T1 (el) Εισπνεομενα σκευασματα τυπου διαλυματος με αλαστιοτροπιου
BR0114379A (pt) Derivados de c-ciclohexilmetilamina substituìdos
AR018162A1 (es) Pirroles substituidos, composicion farmaceutica y el uso de los mismos para la preparacion de dicha composicion farmaceutica
AR038985A1 (es) Parecoxib sodico cristalino
DE60132511D1 (de) E-isomeren von fullerenderivate
ES2086677T3 (es) Composiciones que contienen un gliceroglicolipido.
UY27034A1 (es) Derivados de pirimidina
CR6078A (es) Formulaciones plaguicidas que contienen tensoactivos de acido sulfonico aromatico neutralizado con amina alcoxilada
PT1194136E (pt) Composicao nao solida para aplicacao local compreendendo glicerol e extracto de alchemilla vulgaris

Legal Events

Date Code Title Description
FC Refusal